Enterprise Value
373.2M
Cash
147.8M
Avg Qtr Burn
-26.49M
Short % of Float
4.55%
Insider Ownership
4.06%
Institutional Own.
87.82%
Qtr Updated
03/31/23
Drug Pipeline
Powered by

Only showing assets and stage. See catalyst data with a free or premium account. Unlock more data with a free account.
Drug & Indication | Stage & Event | Catalyst Date |
---|---|---|
TN-201 Details Hypertrophic cardiomyopathies | Phase 1b Initiation | |
TN-301 Details Heart failure | Phase 1 Data readout |